Related references
Note: Only part of the references are listed.Update on lupus epidemiology: advancing health disparities research through the study of minority populations
Cristina Drenkard et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
Jodi L. Karnell et al.
ADVANCED DRUG DELIVERY REVIEWS (2019)
Current challenges in the development of new treatments for lupus
Maria Dall'Era et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada
Francis Fatoye et al.
RHEUMATOLOGY INTERNATIONAL (2018)
Gender Bias in Human Systemic Lupus Erythematosus: A Problem of Steroid Receptor Action?
Virginia Rider et al.
FRONTIERS IN IMMUNOLOGY (2018)
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE
A. M. Al Dhanhani et al.
LUPUS (2017)
The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project
Maria Dall'Era et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles
Chris Chamberlain et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Gender balance in patients with systemic lupus erythematosus
Audrey A. Margery-Muir et al.
AUTOIMMUNITY REVIEWS (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A critical review of clinical trials in systemic lupus erythematosus
M. A. Mahieu et al.
LUPUS (2016)
The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012
Frances Rees et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Autoantibodies in SLE: Specificities, Isotypes and Receptors
Barbara Dema et al.
ANTIBODIES (2016)
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ozan Unlu et al.
EUROPEAN JOURNAL OF RHEUMATOLOGY (2016)
First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus
A. Tocoian et al.
LUPUS (2015)
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study
Anthony Shock et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ian N. Bruce et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects
Lewis L. Judd et al.
AMERICAN JOURNAL OF PSYCHIATRY (2014)
Prevalence of systemic lupus erythematosus and risk factors in rural areas of Anhui Province
Yan-Feng Zou et al.
RHEUMATOLOGY INTERNATIONAL (2014)
Glucocorticoid use and abuse in SLE
Guillermo Ruiz-Irastorza et al.
RHEUMATOLOGY (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice
Liza Robles-Carrillo et al.
JOURNAL OF IMMUNOLOGY (2010)
Epidemiology of systemic lupus erythematosus in Asia
E. Osio-Salido et al.
LUPUS (2010)
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard A. Furie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Mechanisms of disease: Systemic lupus erythematosus
Anisur Rahman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Combining multiple comparisons and modeling techniques in dose-response studies
F Bretz et al.
BIOMETRICS (2005)
The role of CD40 ligand in systemic lupus erythematosus
J Yazdany et al.
LUPUS (2004)
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
DT Boumpas et al.
ARTHRITIS AND RHEUMATISM (2003)
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions
AC Grammer et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus
WQ Huang et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
